Identification of glypican-3-derived long peptides activating both CD8+ and CD4+ T cells; prolonged overall survival in cancer patients with Th cell response

OncoImmunology

Volumn 5, Issue 1, 2016, Pages

  Sayem, Mohammad A ^a,b   Tomita, Yusuke ^a   Yuno, Akira ^a   Hirayama, Masatoshi ^a   Irie, Atsushi ^a   Tsukamoto, Hirotake ^a   Senju, Satoru ^a   Yuba, Eiji ^c   Yoshikawa, Toshiaki ^d   Kono, Kenji ^c   Nakatsura, Tetsuya ^d   Nishimura, Yasuharu ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b MAWLANA BHASHANI SCIENCE AND TECHNOLOGY UNIVERSITY   (Bangladesh)

^c Osaka Prefecture University   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Cancer immunotherapy; CD4+ T cell; Glypican 3; Hepatocellular carcinoma; T cell epitope

Indexed keywords

GAMMA INTERFERON; GLYPICAN 3; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LEUKOCYTE ANTIGEN;

ANIMAL CELL; ANTIGENICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS PRESENTATION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LIVER CELL CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SEQUENCE ANALYSIS;

EID: 84954445404     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1062209     Document Type: Article

References (50)

1. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53:1020-2; PMID:21374666; http://dx. doi. org/10. 1002/hep. 24199
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-90; PMID:18650514; http://dx. doi. org/10. 1056/ NEJMoa0708857
3. Mancuso A, Mazzarelli C, Perricone G, Zavaglia C. Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue. J Hepatol 2014; 60:681; PMID:24216445; http://dx. doi. org/ 10. 1016/j. jhep. 2013. 10. 030
4. Morimoto M, Numata K, Kondo M, Hidaka H, Takada J, Shibuya A, Kobayashi S, Ohkawa S, Okuse C, Morita S et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res 2011; 41:296-302; PMID:21348907; http://dx. doi. org/ 10. 1111/j. 1872-034X. 2011. 00778. x
5. Okabe H, Satoh S, Kato T, Kitahara O, Yanagawa R, Yamaoka Y, Tsunoda T, Furukawa Y, Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001; 61:2129-37; PMID:11280777.
6. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003; 306:16-25; PMID:12788060; http://dx. doi. org/ 10. 1016/S0006-291X(03)00908-2
7. Capurro MI, Xiang YY, Lobe C, Filmus J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res 2005; 65:6245-54; PMID:16024626; http://dx. doi. org/ 10. 1158/0008-5472. CAN-04-4244
8. Sawada Y, Yoshikawa T, Nobuoka D, Shirakawa H, Kuronuma T, Motomura Y, Mizuno S, Ishii H, Nakachi K, Konishi M et al. Phase I trial of a glypican-3-derived peptide vaccine for advanced hepatocellular carcinoma: immunologic evidence and potential for improving overall survival. Clin Cancer Res 2012; 18:3686-96; PMID:22577059; http://dx. doi. org/ 10. 1158/1078-0432. CCR-11-3044
9. Komori H, Nakatsura T, Senju S, Yoshitake Y, Motomura Y, Ikuta Y, Fukuma D, Yokomine K, Harao M, Beppu T et al. Identification of HLA-A2-or HLAA24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma. Clin Cancer Res 2006; 12:2689-97; PMID:16675560; http://dx. doi. org/10. 1158/1078-0432. CCR-05-2267
10. Toes RE, Blom RJ, Offringa R, Kast WM, Melief CJ. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 1996; 156:3911-8; PMID:8621930
11. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A 1996; 93:7855-60; PMID:8755566; http://dx. doi. org/10. 1073/pnas. 93. 15. 7855
12. Srinivasan M, Domanico SZ, Kaumaya PT, Pierce SK. Peptides of 23 residues or greater are required to stimulate a high affinity class II-restricted T cell response. Eur J Immunol 1993; 23:1011-6; PMID:8386663; http://dx. doi. org/10. 1002/eji. 1830230504
13. Sercarz EE, Maverakis E. Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 2003; 3:621-9; PMID:12974477; http://dx. doi. org/ 10. 1038/nri1149
14. Kayaga J, Souberbielle BE, Sheikh N, Morrow WJ, Scott-Taylor T, Vile R, Chong H, Dalgleish AG. Antitumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Ther 1999; 6:1475-81; PMID:10467372; http:// dx. doi. org/10. 1038/sj. gt. 3300961
15. +T cells against NY-ESO-1. N Engl J Med 2008; 358:2698-703; PMID:18565862; http:// dx. doi. org/10. 1056/NEJMoa0800251
16. +T cells. J Exp Med 2004; 200:701-12; PMID:15381726; http:// dx. doi. org/10. 1084/jem. 20041270
17. Chamoto K, Tsuji T, Funamoto H, Kosaka A, Matsuzaki J, Sato T, Abe H, Fujio K, Yamamoto K, Kitamura T et al. Potentiation of tumor eradication by adoptive immunotherapy with T-cell receptor gene-transduced T-helper type 1 cells. Cancer Res 2004; 64:386-90; PMID:14729649; http://dx. doi. org/10. 1158/0008-5472. CAN-03-2596
18. +T-cell response. Nat Rev Immunol 2004; 4:595-602; PMID:15286726; http:// dx. doi. org/10. 1038/nri1413
19. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001; 97:192-7; PMID:11133760; http://dx. doi. org/ 10. 1182/blood. V97. 1. 192
20. +T lymphocytes. Cancer Res 2010; 70:8368-77; PMID:20940398; http://dx. doi. org/ 10. 1158/0008-5472. CAN-10-1322
21. Melief CJ, van der Burg SH. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer 2008; 8:351-60; PMID:18418403; http://dx. doi. org/10. 1038/nrc2373
22. Brunsvig PF, Kyte JA, Kersten C, Sundstrom S, Moller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res 2011; 17:6847-57; PMID:21918169; http://dx. doi. org/10. 1158/1078-0432. CCR-11-1385
23. Kyte JA, Gaudernack G, Dueland S, Trachsel S, Julsrud L, Aamdal S. Telomerase peptide vaccination combined with temozolomide: a clinical trial in stage IV melanoma patients. Clin Cancer Res 2011; 17:4568-80; PMID:21586625; http://dx. doi. org/10. 1158/ 1078-0432. CCR-11-0184
24. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 2000; 56:522-9; PMID:11169242; http://dx. doi. org/10. 1034/j. 1399-0039. 2000. 560606. x
25. Mack SJ, Bugawan TL, Moonsamy PV, Erlich JA, Trachtenberg EA, Paik YK, Begovich AB, Saha N, Beck HP, Stoneking M et al. Evolution of Pacific/Asian populations inferred from HLA class II allele frequency distributions. Tissue Antigens 2000; 55:383-400; PMID:10885559; http://dx. doi. org/10. 1034/j. 1399-0039. 2000. 550501. x
26. Harao M, Hirata S, Irie A, Senju S, Nakatsura T, Komori H, Ikuta Y, Yokomine K, Imai K, Inoue M et al. HLA-A2-restricted CTL epitopes of a novel lung cancer-associated cancer testis antigen, cell division cycle associated 1, can induce tumor-reactive CTL. Int J Cancer 2008; 123:2616-25; PMID:18770861; http://dx. doi. org/10. 1002/ijc. 23823
27. Tomita Y, Harao M, Senju S, Imai K, Hirata S, Irie A, Inoue M, Hayashida Y, Yoshimoto K, Shiraishi K et al. Peptides derived from human insulin-like growth factor-II mRNA binding protein 3 can induce human leukocyte antigen-A2-restricted cytotoxic T lymphocytes reactive to cancer cells. Cancer Sci 2011; 102:71-8; PMID:21087352; http://dx. doi. org/10. 1111/j. 1349-7006. 2010. 01780. x
28. Sawada Y, Yoshikawa T, Fujii S, Mitsunaga S, Nobuoka D, Mizuno S, Takahashi M, Yamauchi C, Endo I, Nakatsura T. Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination: An autopsy case. Hum Vaccin Immunother 2013; 9:1228-33; PMID:23466818; http://dx. doi. org/10. 4161/hv. 24179
29. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300:339-42; PMID:12690202; http://dx. doi. org/10. 1126/science. 1083317
30. +T-cell immunity in patients with malignant tumor. Clin Cancer Res 2013; 19:4508-20; PMID:23714729; http://dx. doi. org/ 10. 1158/1078-0432. CCR-13-0197
31. +T-cell immunity in cancer patients. Int J Cancer 2014; 134:352-66; PMID:24734272; http://dx. doi. org/10. 1002/ijc. 28376
32. Nishimura Y, Tomita Y, Yuno A, Yoshitake Y, Shinohara M. Cancer immunotherapy using novel tumorassociated antigenic peptides identified by genomewide cDNA microarray analyses. Cancer Sci 2015; 106 (5):505-11; PMID:25726868; http://dx. doi. org/ 10. 111/cas. 12650
33. Tomita Y, Yuno A, Tsukamoto H, Senju S, Kuroda Y, Hirayama M, Imamura Y, Yatsuda J, Sayem MA, Irie A et al. Identification of immunogenic LY6K long peptide encompassing both CD4 and CD8 T-cell epitopes and eliciting CD4 T-cell immunity in patients with malignant disease. Oncoimmunology 2014; 3:e28100; PMID:25340007; http://dx. doi. org/10. 4161/ onci. 28100
34. Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, Nagata M, Takamune Y, Kawahara K, Nakagawa Y et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res 2015; 21:312-21; PMID:25391695; http://dx. doi. org/ 10. 1158/1078-0432. CCR-14-0202
35. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361:1838-47; PMID:19890126; http://dx. doi. org/10. 1056/ NEJMoa0810097
36. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013; 494:361-5; PMID:23376950; http://dx. doi. org/10. 1038/ nature11824
37. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2002; 2:85-95; PMID:11910899; http://dx. doi. org/10. 1038/nri724
38. Yuba E, Harada A, Sakanishi Y, Watarai S, Kono K. A liposome-based antigen delivery system using pH-sensitive fusogenic polymers for cancer immunotherapy. Biomaterials 2013; 34:3042-52; PMID:23374704; http://dx. doi. org/10. 1016/j. biomaterials. 2012. 12. 031
39. Harris RC, Chianese-Bullock KA, Petroni GR, Schaefer JT, Brill LB, 2nd, Molhoek KR, Deacon DH, Patterson JW, Slingluff CL, Jr. The vaccine-site microenvironment induced by injection of incomplete Freund's adjuvant, with or without melanoma peptides. J Immunother 2012; 35:78-88; PMID:22130163; http://dx. doi. org/10. 1097/CJI. 0b013e31823731a4
40. Kappes D, Strominger JL. Human class II major histocompatibility complex genes and proteins. Annu Rev Biochem 1988; 57:991-1028; PMID:3140715; http:// dx. doi. org/10. 1146/annurev. bi. 57. 070188. 005015
41. Southwood S, Sidney J, Kondo A, del Guercio MF, Appella E, Hoffman S, Kubo RT, Chesnut RW, Grey HM, Sette A. Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol 1998; 160:3363-73; PMID:9531296
42. Nakajima F, Nakamura J, Yokota T. Analysis of HLA haplotypes in Japanese, using high resolution allele typing. MHC 2001; 8:1-32.
43. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx. doi. org/ 10. 1200/JCO. 2010. 30. 5425
44. McKinney DM, Southwood S, Hinz D, Oseroff C, Arlehamn CS, Schulten V, Taplitz R, Broide D, Hanekom WA, Scriba TJ et al. A strategy to determine HLA class II restriction broadly covering the DR, DP, and DQ allelic variants most commonly expressed in the general population. Immunogenetics 2013; 65:357-70; PMID:23392739; http://dx. doi. org/10. 1007/s00251-013-0684-y
45. Wang P, Sidney J, Kim Y, Sette A, Lund O, NielsenM, Peters B. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 2010; 11:568; PMID:21092157; http://dx. doi. org/10. 1186/ 1471-2105-11-568
46. Tomita Y, Imai K, Senju S, Irie A, Inoue M, Hayashida Y, Shiraishi K, Mori T, Daigo Y, Tsunoda T et al. A novel tumor-associated antigen, cell division cycle 45-like can induce cytotoxic T-lymphocytes reactive to tumor cells. Cancer Sci 2011; 102:697-705; PMID:21231984; http://dx. doi. org/10. 1111/j. 1349-7006. 2011. 01865. x
47. Yuba E, Kono Y, Harada A, Yokoyama S, Arai M, Kubo K, Kono K. The application of pH-sensitive polymer-lipids to antigen delivery for cancer immunotherapy. Biomaterials 2013; 34:5711-21; PMID:23639528; http://dx. doi. org/10. 1016/j. biomaterials. 2013. 04. 007
48. Inoue M, Senju S, Hirata S, Ikuta Y, Hayashida Y, Irie A, Harao M, Imai K, Tomita Y, Tsunoda T et al. Identification of SPARC as a candidate target antigen for immunotherapy of various cancers. Int J Cancer 2010; 127:1393-403; PMID:20063317; http://dx. doi. org/ 10. 1002/ijc. 25160
49. +T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus. Hum Immunol 1998; 59:549-60; PMID:9757911; http://dx. doi. org/10. 1016/S0198-8859(98)00050-0
50. +T lymphocytes from beta2 microglobulin (beta2m) HLA-A2. 1 monochain transgenic H-2Db beta2m double knockout mice. J Exp Med 1997; 185:2043-51; PMID:9182675; http://dx. doi. org/10. 1084/ jem. 185. 12. 2043